Company Overview and News
Alaska's North Slope receives little attention give the focus on North America unconventionals. In recent months, the North Slope has quietly been attracting investment and activity. Kareemah Mohamed, an expert in basin strategies and resource evaluation, provides an overview of the North Slope, including key players and opportunities for operators in our Upstream in Perspective podcast series. Here's an excerpt of the conversation [full podcasts below]:
COP PBT OXY
Petrobras – Petroleo Brasileiro S.A. (PBR) (NYSE:PBR) has been so volatile it might make investors sick. Some might be asking whether they’re riding a roller coaster or are long on PBR stock.
UPS XOM PXD FDX GOOG PBR EOG COP X GOOGL CVX OIH
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE
Warren Buffett clearly knows his way around the stock market. There’s no reason to go over America’s favorite value investor’s history of great returns and generating gains for Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B). But it is worth repeating how he generated those mega-sized returns.
COP BRK.A PSXP
Lilis Energy, Inc. (LLEX - Free Report) recently entered into an acreage swap transaction in a bid to upgrade its portfolio in the Permian Basin. The pure-play Permian operator is set to trade its non-operated holdings with 1,500 acres of West Texas land in the Delaware Basin. The company, with which it has entered into the swap deal, has not been undisclosed yet. Subject to satisfactory closing conditions, the deal is set for closure by the end of July.
COP APA LMHA LLEX LMHB LM
Chicago, IL – June 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United Technologies (UTX - Free Report) , PayPal (PYPL - Free Report) , ConocoPhillips (COP - Free Report) , Raytheon (RTN - Free Report) and Tesla (TSLA - Free Report) .
ELY BCS OIL ACCO LXFR WTW UTX GIII MAR.WI COP MAR 83SF DK 83SK ENBL URBN HLT KOS AAXN 47MC
Investors focused on the Oils-Energy space have likely heard of ConocoPhillips (COP - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of COP and the rest of the Oils-Energy group's stocks.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies (UTX), PayPal (PYPL) and ConocoPhillips (COP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
COF.PRG COF.PRH BCS OIL COF.WS COF.PRP COP COF-D 83SF COF-C COF-F 83SK ICE COF.PRC COF.PRD 47MC COF.PRF COF-P UNP LNC.WS COF UTX ANTM PVH LNC OXY
Crude oil has been trading near $66 a barrel early on Tuesday. This is the lowest that crude oil has been at since mid-April. This comes after oil reached above $70 in late May for the first time in years. If anything, this drop might offer some stabilization, but how quickly oil will recover and then some is yet to be seen. The current crude price still pales in comparison to what it was in 2014.
COP BP XOM CVX BP BPAQF OXY PBR BP.A BP.B
This is the seventh month I have officially tracked the taxable account's dividend income, and it was slightly below expectations with a total of $1,642.46 of dividends received.
SOJA ETP.PRC GIS EBGUF XOM IDCC EPR.PRG O.PRF SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR EEP SO TLP WLK O MSB CMI WLKP ENB ETP SPG.PRJ HP PEP ORI SPG WPC ADM
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now.
SGEN PK WFCNP APA SPWR XEC DTE NXPI WFC.PRL 5GD DTJ WFC.PRJ COP WFC.PRT MTCH WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX KOS WFC.PRW WFC.PRV MO FRAC WFC WFC.WS OLN INCY SRGRF OAS DTW DTV FDC EEFT TRI SEMG DTY
10h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to COP / ConocoPhillips on message board site Silicon Investor.
as of ET